 Receptor, erbB-2
"Receptor, erbB-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cell surface protein-tyrosine kinase receptor that is found to be overexpressed in a significant number of adenocarcinomas. It has extensive homology to and can heterodimerize with the EGF receptor (RECEPTOR, EPIDERMAL GROWTH FACTOR), the erbB-3 receptor (RECEPTOR, ERBB-3) and the erbB-4 receptor. Activation of the erbB-2 receptor occurs during heterodimer formation with a ligand-bound erbB receptor family members.
| Descriptor ID |
D018719
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.150 D12.776.543.750.060.374 D12.776.543.750.750.400.350 D12.776.624.664.700.642 D23.101.840.642
|
| Concept/Terms |
Receptor, erbB-2- Receptor, erbB-2
- Receptor, erbB 2
- erbB-2 Receptor
- erbB-2 Proto-Oncogene Protein
- Proto-Oncogene Protein, erbB-2
- erbB 2 Proto Oncogene Protein
- erbB-2 Receptor Protein-Tyrosine Kinase
- erbB 2 Receptor Protein Tyrosine Kinase
- HER-2 Proto-Oncogene Protein
- HER 2 Proto Oncogene Protein
- Proto-Oncogene Protein, HER-2
- neu Proto-Oncogene Protein
- Proto-Oncogene Protein, neu
- neu Proto Oncogene Protein
- Receptors, erbB-2
- Receptors, erbB 2
- erbB-2 Receptors
- Oncogene Protein HER-2
- Oncogene Protein HER 2
- p185(c-neu)
- Proto-Oncogene Protein HER-2
- Proto Oncogene Protein HER 2
- Proto-Oncogene Protein p185(neu)
- Proto-Oncogene Proteins c-erbB-2
- Proto Oncogene Proteins c erbB 2
- Receptor, neu
- c-erbB-2 Protein
- c erbB 2 Protein
- neu Receptor
|
Below are MeSH descriptors whose meaning is more general than "Receptor, erbB-2".
- Chemicals and Drugs [D]
- Enzymes and Coenzymes [D08]
- Enzymes [D08.811]
- Transferases [D08.811.913]
- Phosphotransferases [D08.811.913.696]
- Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
- Protein Kinases [D08.811.913.696.620.682]
- Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
- Receptor Protein-Tyrosine Kinases [D08.811.913.696.620.682.725.400]
- Receptor, erbB-2 [D08.811.913.696.620.682.725.400.150]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptor Protein-Tyrosine Kinases [D12.776.543.750.060]
- Receptor, erbB-2 [D12.776.543.750.060.374]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Growth Factor [D12.776.543.750.750.400]
- Receptor, erbB-2 [D12.776.543.750.750.400.350]
- Neoplasm Proteins [D12.776.624]
- Oncogene Proteins [D12.776.624.664]
- Proto-Oncogene Proteins [D12.776.624.664.700]
- Receptor, erbB-2 [D12.776.624.664.700.642]
- Biological Factors [D23]
- Biological Markers [D23.101]
- Tumor Markers, Biological [D23.101.840]
- Receptor, erbB-2 [D23.101.840.642]
Below are MeSH descriptors whose meaning is more specific than "Receptor, erbB-2".
This graph shows the total number of publications written about "Receptor, erbB-2" by people in this website by year, and whether "Receptor, erbB-2" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 0 | 1 | 1 | | 1993 | 0 | 1 | 1 | | 1999 | 0 | 1 | 1 | | 2002 | 0 | 4 | 4 | | 2003 | 2 | 0 | 2 | | 2004 | 1 | 0 | 1 | | 2005 | 2 | 0 | 2 | | 2006 | 2 | 1 | 3 | | 2007 | 3 | 0 | 3 | | 2008 | 2 | 2 | 4 | | 2009 | 2 | 0 | 2 | | 2010 | 5 | 3 | 8 | | 2011 | 2 | 3 | 5 | | 2012 | 4 | 3 | 7 | | 2013 | 2 | 5 | 7 | | 2014 | 1 | 6 | 7 | | 2015 | 6 | 4 | 10 | | 2016 | 5 | 5 | 10 | | 2017 | 4 | 9 | 13 | | 2018 | 3 | 7 | 10 | | 2019 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptor, erbB-2" by people in Profiles.
-
Bao J, Donovan C, Amersi F, Zhang X, Giuliano AE, Chung A. Outcomes in patients with small node-negative invasive breast cancer. Breast J. 2019 07; 25(4):638-643.
-
Klempner SJ, Catenacci DVT. Variety Is the Spice of Life, but Maybe Not in Gastroesophageal Adenocarcinomas. Cancer Discov. 2019 02; 9(2):166-168.
-
Montefiori LE, Nobrega MA. Gene therapy for pathologic gene expression. Science. 2019 01 18; 363(6424):231-232.
-
Ibraheem AF, Press DJ, Olopade OI, Huo D. Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy? Cancer. 2019 01 15; 125(2):213-222.
-
Pitt JJ, Riester M, Zheng Y, Yoshimatsu TF, Sanni A, Oluwasola O, Veloso A, Labrot E, Wang S, Odetunde A, Ademola A, Okedere B, Mahan S, Leary R, Macomber M, Ajani M, Johnson RS, Fitzgerald D, Grundstad AJ, Tuteja JH, Khramtsova G, Zhang J, Sveen E, Hwang B, Clayton W, Nkwodimmah C, Famooto B, Obasi E, Aderoju V, Oludara M, Omodele F, Akinyele O, Adeoye A, Ogundiran T, Babalola C, MacIsaac K, Popoola A, Morrissey MP, Chen LS, Wang J, Olopade CO, Falusi AG, Winckler W, Haase K, Van Loo P, Obafunwa J, Papoutsakis D, Ojengbede O, Weber B, Ibrahim N, White KP, Huo D, Olopade OI, Barretina J. Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features. Nat Commun. 2018 10 16; 9(1):4181.
-
Lee SS, Bindokas VP, Kron SJ. Multiplex Three-Dimensional Mapping of Macromolecular Drug Distribution in the Tumor Microenvironment. Mol Cancer Ther. 2019 01; 18(1):213-226.
-
Santa-Maria CA, Nanda R. Immune Checkpoint Inhibitor Therapy in Breast Cancer. J Natl Compr Canc Netw. 2018 10; 16(10):1259-1268.
-
Van Swearingen AED, Siegel MB, Deal AM, Sambade MJ, Hoyle A, Hayes DN, Jo H, Little P, Dees EC, Muss H, Jolly T, Zagar TM, Patel N, Miller CR, Parker JS, Smith JK, Fisher J, Shah N, Nabell L, Nanda R, Dillon P, Abramson V, Carey LA, Anders CK. LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases. Breast Cancer Res Treat. 2018 Oct; 171(3):637-648.
-
Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, Gómez HL, Tondini C, Ciruelos E, Burstein HJ, Bonnefoi HR, Bellet M, Martino S, Geyer CE, Goetz MP, Stearns V, Pinotti G, Puglisi F, Spazzapan S, Climent MA, Pavesi L, Ruhstaller T, Davidson NE, Coleman R, Debled M, Buchholz S, Ingle JN, Winer EP, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Goldhirsch A, Regan MM. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med. 2018 Jul 12; 379(2):122-137.
-
Li D, McCall LM, Hahn OM, Hudis CA, Cohen HJ, Muss HB, Jatoi A, Lafky JM, Ballman KV, Winer EP, Tripathy D, Schneider B, Barry W, Dickler MN, Hurria A. Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study. Breast Cancer Res Treat. 2018 Sep; 171(2):325-334.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|